Savara (SVRA) Expected to Release Earnings on Wednesday

Key Points

• Savara is expected to report Q3 2026 results after market close on November 11; analysts forecast a loss of $0.1633 per share and revenue of $0.50 million.
• In its previous quarter, the company reported a $0.16-per-share loss, missing the consensus estimate of a $0.14 loss. Analysts project losses of $0.66 per share for the current fiscal year and $0.32 next year.
• MarketBeat analysts have a “Moderate Buy” consensus on SVRA, with an average price target of $10.25; seven analysts rate it Buy and one Sell.

Savara (NASDAQ:SVRA - Get Free Report) will likely be issuing its Q3 2026 results after the market closes on Wednesday, November 11th. Analysts expect Savara to post earnings of ($0.1633) per share and revenue of $0.50 million for the quarter. Investors are encouraged to explore the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 11, 2026 at 4:00 PM ET.

Savara (NASDAQ:SVRA - Get Free Report) last issued its earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). On average, analysts expect Savara to post ($0.66) EPS for the current fiscal year and ($0.32) EPS for the next fiscal year.

Savara Stock Performance

Shares of NASDAQ SVRA opened at $4.75 on Wednesday. The firm's 50 day moving average price is $5.04 and its 200-day moving average price is $5.39. Savara has a 52-week low of $3.86 and a 52-week high of $7.01. The company has a current ratio of 10.13, a quick ratio of 10.13 and a debt-to-equity ratio of 0.21.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the stock. JPMorgan Chase & Co. assumed coverage on shares of Savara in a report on Wednesday, October 7th. They issued an "overweight" rating and a $12.00 price objective for the company. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Savara in a research report on Thursday, October 15th. Royal Bank Of Canada set a $10.00 target price on Savara in a research note on Wednesday, October 7th. Wall Street Zen lowered Savara from a "hold" rating to a "sell" rating in a report on Sunday, October 4th. Finally, Citigroup reissued a "market outperform" rating on shares of Savara in a report on Wednesday, October 7th. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, Savara currently has a consensus rating of "Moderate Buy" and an average target price of $10.25.

Savara Company Profile

Savara Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare respiratory diseases. The company's work is centered on conditions with significant unmet medical needs, particularly diseases involving impaired lung function and abnormal accumulation of material in the lungs.

Savara's lead product candidate is molgramostim, an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). The therapy is being developed for autoimmune pulmonary alveolar proteinosis, a rare lung disorder in which surfactant accumulates in the airspaces and interferes with breathing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.